Published in Bone Marrow Transplant on June 01, 1998
Allogeneic T cells induce rapid CD34+ cell differentiation into CD11c+CD86+ cells with direct and indirect antigen-presenting function. Blood (2006) 0.77
Clinical grade isolation of regulatory T cells from G-CSF mobilized peripheral blood improves with initial depletion of monocytes. Am J Blood Res (2015) 0.75
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med (2001) 3.98
Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood (2000) 3.85
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med (1992) 3.77
Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood (1984) 3.65
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood (2001) 3.32
Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol (1991) 3.21
Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood (1998) 3.06
Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med (1993) 2.71
HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med (1996) 2.52
Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med (1998) 2.36
Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant (2006) 2.32
A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood (1990) 2.32
Antitumor vaccination: where we stand. Haematologica (2000) 2.30
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood (1992) 2.14
Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood (1990) 2.09
The place of bone-marrow transplantation in acute myelogenous leukaemia. Lancet (1980) 2.03
Long-term results of the surgical treatment of spinal dermoid and epidermoid tumors. Neurosurgery (1989) 1.94
Guidelines for the use of recombinant human erythropoietin. Haematologica (1995) 1.94
Primary intestinal lymphoma: clinical and therapeutic features of 32 patients. Haematologica (1997) 1.88
Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol (1995) 1.77
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 1.67
Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood (1997) 1.65
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood (1997) 1.64
Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol (1996) 1.64
Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood (1991) 1.61
All-trans-retinoic acid and pseudotumor cerebri in a young adult with acute promyelocytic leukemia: a possible disease association. Haematologica (1996) 1.61
Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood (1994) 1.57
The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol (1999) 1.54
Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol (1996) 1.54
Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother (1991) 1.49
Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol (1995) 1.49
Intradural extramedullary cavernous angioma: case report. Neurosurgery (1991) 1.48
Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol (1998) 1.48
Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant (1995) 1.47
New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica (1997) 1.47
Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia (2003) 1.47
Marrow transplantation from unrelated donors. Curr Opin Hematol (1995) 1.45
Induction of calcium flux and enhancement of cytolytic activity in natural killer cells by cross-linking of the sheep erythrocyte binding protein (CD2) and the Fc-receptor (CD16). J Immunol (1987) 1.42
A comparison of computerized tomography-guided stereotactic and ultrasound-guided techniques for brain biopsy. J Neurosurg (1991) 1.41
Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation (2001) 1.41
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res (2010) 1.40
A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. Haematologica (1999) 1.39
In situ staining of bromodeoxyuridine positive cells in normal and neoplastic colony-forming units grown on plasma clots. J Immunol Methods (1988) 1.38
[Sir Robert is no more]. Rev Esp Anestesiol Reanim (1990) 1.37
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36
Arachnoid diverticula: a unitary approach to spinal cysts communicating with the subarachnoid space. Acta Neurochir (Wien) (1977) 1.35
Glossopharyngeal neuralgia with cardiac syncope. Neurosurgery (1995) 1.35
Leber's hereditary optic neuropathy: biochemical effect of 11778/ND4 and 3460/ND1 mutations and correlation with the mitochondrial genotype. Neurology (1997) 1.34
Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood (2000) 1.32
The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood (1995) 1.31
Nonsecretory multiple myeloma. Presenting findings, clinical course and prognosis. Acta Haematol (1985) 1.30
Long-term results of surgical treatment of myelopathy due to cervical spondylosis. J Neurosurg (1969) 1.29
The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol (1999) 1.29
Intradural spinal cysts. Acta Neurochir (Wien) (1983) 1.29
The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. Br J Haematol (2001) 1.28
Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood (1996) 1.27
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol (1999) 1.27
5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2009) 1.26
The Notch ligand, Delta-1, inhibits the differentiation of monocytes into macrophages but permits their differentiation into dendritic cells. Blood (2001) 1.26
Monocytes express high amounts of Notch and undergo cytokine specific apoptosis following interaction with the Notch ligand, Delta-1. Blood (2000) 1.26
Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann Oncol (1997) 1.26
Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood (1996) 1.25
Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant (2001) 1.25
Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. Blood (2001) 1.24
Primary spinal neoplasms in childhood: analysis of 1234 published cases (including 56 personal cases) by pathology, sex, age and site. Differences from the situation in adults. Neurochirurgia (Stuttg) (1982) 1.24
Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood (1997) 1.23
Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood (1988) 1.23
Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood (2000) 1.22
Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2007) 1.21
Cerebral hydatidosis in childhood: a retrospective survey with emphasis on long-term follow-up. Neurosurgery (1991) 1.21
Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant (2000) 1.21
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant (2010) 1.19
Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol (2000) 1.18
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Haematologica (2001) 1.16
Staging and prognosis in chronic myelogenous leukemia. Semin Hematol (1988) 1.15
Increase in T gamma lymphocytes in B-cell chronic lymphocytic leukaemia. II. Correlation with clinical stage and findings in B-prolymphocytic leukaemia. Br J Haematol (1981) 1.15
Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci U S A (1996) 1.14
Pneumocephalus and tension pneumocephalus after posterior fossa surgery in the sitting position: a prospective study. Acta Neurochir (Wien) (1986) 1.14
Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood (1997) 1.13
Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood (1993) 1.10
Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood (2000) 1.10
Unrelated donor marrow transplants for severe acquired aplastic anemia. Bone Marrow Transplant (1992) 1.09
Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J Immunol (2000) 1.09